Paladin Labs Acquires Allon Therapeutics

Vancouver-based Allon Therapeutics Inc. (TSX: NPC), which is focused on bringing to market central nervous system therapies, has been acquired for an undisclosed sum by Paladin Labs Inc. (TSX:PLB), a specialty pharmaceuticals company based in Montréal. Allon Therapeutics earlier this year filed a proposal for bankruptcy and reorganization. The company was backed by Canadian venture capital firm NDI Capital and other investors.


Paladin Labs Inc. (TSX:PLB) (“Paladin” and/or the “Company”), a leading Canadian specialty pharmaceutical company, and Allon Therapeutics Inc. announced today that in accordance with the Order for Reorganization in Allon’s proposal proceedings under the Bankruptcy and Insolvency Act (Canada) and under the Canada Business Corporations Act which have been previously announced, Paladin has become the sole shareholder of Allon.

Immediately prior to Paladin becoming the sole shareholder of Allon, all existing issued and outstanding shares and other securities of Allon were, pursuant to the Court Order, cancelled without payment or other consideration. One of the other consequences of Paladin becoming the sole shareholder of Allon is that Allon will cease being a reporting issuer in Canada.

Please also refer to the Allon’s press releases dated May 30 and July 10, 2013 related to additional background on the transaction.

About Paladin Labs Inc.

Paladin Labs Inc., headquartered in Montreal, Canada, is a leading specialty pharmaceutical company focused on developing, acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada’s leading specialty pharmaceutical companies. Paladin’s shares trade on the Toronto Stock Exchange under the symbol PLB. For more information about Paladin, please visit the Paladin Web Site at

Forward Looking Statement

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be
reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report as well as in the Company’s Annual Information Form for the year ended December 31, 2012. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company’s ongoing quarterly filings, annual report and Annual Information Form and other fillings found on SEDAR at

Paladin Labs Inc.
Samira Sakhia, CPA, CA, MBA
Chief Financial Officer
Tel: 514-669-5367
514-344-4675 (FAX)

SOURCE: Paladin Labs Inc. and Allon Therapeutics Inc.

Photo courtesy of Shutterstock.